Skip to main content

Branded

  • Biotech stocks drop after Trump promises to ‘bring down drug prices’
    NEW YORK — Biotech stocks closed largely down on Tuesday, following a day of trading that began with a 2.5% drop in the SPDR S&P Biotech XBI index. The XBI closed down 4.02% and iShares Nasdaq Biotechnology ETF IBB closed down 2.94%. This is as the S&P closed up 1.32% and the Nasdaq closed up 1.14%. 
     

  • QuintilesIMS Institute report examines global spending trends through 2020
    DANBURY, Conn. and RESEARCH TRIANGLE PARK, N.J. — The latest report from the QuintilesIMS Institute for Health for Healthcare Informatics is taking a look at how spending on medicines will change through 2021. The “Outlook for Global Medicines Through 2021: Balancing Cost and Value” report projects that total global spending will be close to $1.5 trillion on an invoice price basis through 2021. As this happens, the compound annual growth rate is expected to moderate, rising between 4% and 7% by 2021, compared to the 9% CAGR in 2014 and 2015. 

  • Diplomat to dispense Darzalex
    FLINT, Mich. — Diplomat Pharmacy will be dispensing Janssen’s Darzalex, the company announced Thursday. The drug will be dispensed in combination with Revlimid (lenalidomide) and dexamethasone or with Velcade (bortezomib) and dexamethasone. 
     
    The drug was approved by the Food and Drug Administration to treat multiple myeloma in patients who have received at least one other treatment. 
     

  • Fruth Pharmacy adds pharmacogenetic offering to its list of services

    POINT PLEASANT, W.Va. -- Fruth Pharmacy on Wednesday announced its pharmacies will now offer Rxight, a broad, comprehensive pharmacogenetic program. The program, developed by MD Labs, will help determine if the medications people take and the dosage levels are right for them based on their DNA. Rxight covers more than 200 prescription and over-the-counter medicines.

  • Impax adds TetraLogic Pharmaceuticals CEO to board
    HAYWARD, Calif. — Impax Laboratories has a new board member. The company announced Monday that it had appointed J. Kevin Buchi, CEO of TetraLogic Pharmaceuticals, to its board of directors. 
     
    “We are pleased to welcome Kevin to our Board,” Impax chairman Robert L. Burr said. “Kevin brings a great deal of pharmaceutical experience as an accomplished executive and director. He will provide valuable insights and perspective with respect to our operations, strategy and corporate governance.”

  • J&J, Actelion Pharamceuticals confirm early talks for reported potential acquisition
    NEW BRUNSWICK, N.J. — On Nov. 25, Bloomberg reported that Johnson & Johnson and Actelion Pharmaceuticals were in discussion over a potential acquisition of Actelion by J&J. Both companies have confirmed that they are in preliminary discussions. 
     

  • FDA approves Novo Nordisk’s Xultophy 100/3.6 for Type 2 diabetes
    SILVER SPRING, Md. — Novo Nordisk announced Monday that the Food and Drug Administration had approved its Xultophy 100/3.6 (insulin degludec 100 units/ML and liraglutide 3.6 mg/mL). The drug is indicated to improve glycemic control in adults with Type 2 diabetes inadequately controlled on less than 50 units of basal insulin daily or less than or equal to 1.8 mg of liraglutide daily. 
     

  • Sanofi’s Soliqua 100/33 for Type 2 diabetes gets FDA nod
    SILVER SPRING, Md. — The Food and Drug Administration has approved Sanofi’s Soliqua 100/33 (insulin glargine 100 units/mL and lixisenatide 33mcg/mL), the company announced Monday. The drug is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 
     
X
This ad will auto-close in 10 seconds